Validity and reliability concerns associated with cardiopulmonary exercise testing young people with cystic fibrosis by Saynor, ZL et al.
1 
 
 
 
Letter to the Editor 
  
 
Letter to the Editor: Validity and reliability concerns associated with cardiopulmonary 
exercise testing young people with cystic fibrosis. Response to: Statement on Exercise 
Testing in Cystic Fibrosis (Hebestreit et al., 2015 Respiration 90(4):332-51) 
 
 
 
Zoe L. Saynor
a*
, Dr. Alan R. Barker
b
, Dr. Patrick J. Oades
c
, Owen W. Tomlinson
b
, Prof. Craig 
Anthony Williams
b
 
 
 
 
 
 
Word count: 995 words 
 
 
 
 
Short Title: Validity and reliability concerns associated with CPET in CF 
 
 
 
 
 
a 
Department of Sport and Exercise Science, University of Portsmouth, Portsmouth, UK. 
 
b Children’s Health and Exercise Research Centre, Sport and Health Sciences, University of 
Exeter, Exeter, Devon, UK. 
 
c 
Paediatric unit, Royal Devon and Exeter NHS Foundation Trust, Exeter, Devon, UK.  
 
*Correspondence to: Z.L. Saynor, Department of Sport and Exercise Science, Spinnaker 
Building, Cambridge Road, University of Portsmouth, Portsmouth, Hampshire, UK. 
Tel: +44 (0)2392 843080 
Email: zoe.saynor@port.ac.uk 
2 
 
The recent statement by Hebestreit and colleagues [1] on behalf of the European Cystic 1 
Fibrosis Society (ECFS) Exercise Working Group and endorsed by the European Respiratory 2 
Society, should be commended for their efforts to establish consensus regarding exercise 3 
testing for young people with CF. Exercise testing is a valuable investigative tool for the the 4 
clinical management and scientific investigation of children and adolescents with CF and this 5 
document provides an international standpoint regarding the importance of cardiopulmonary 6 
exercise testing (CPET) within the management of this patient group. However, it is our view 7 
that the authors have missed an opportunity to provide a contemporary and comprehensive 8 
overview of the CPET ‘toolkit’ currently available.   9 
The authors state that this document will ‘describe the current best practice 10 
recommendations for conducting exercise tests in patients with CF’ and ‘summarises the 11 
information available on specific test protocols and outcome parameters (Page 2)’. The 12 
authors recommend the Godfrey protocol [2] when using the cycle ergometer, with measures 13 
of arterial oxygen saturation and, when possible, pulmonary gas exchange and ventilation. 14 
Whilst this does represent progress from the routinely used shuttle and step tests, the authors 15 
failed to acknowledge several limitations inherent to the Godfrey protocol and the 16 
recommended use of criteria to verify a maximal test. This is surprising, given that the ECFS 17 
Clinical Trials Network Standardisation Committee recently called for research assessing the 18 
validity, reproducibility and feasibility of outcome measures utilised in the assessment of 19 
patients with CF and the most appropriate exercise test for paediatric patients [3].  20 
The authors rightfully acknowledge that an issue with shuttle and step tests is that it can be 21 
difficult to determine whether a maximal effort was made. However, they then state that ‘the 22 
Godfrey protocol provides valid information for all CF relevant indications for an exercise 23 
test’. The authors recommend that since not all individuals display the tradition verification 24 
criterion of a plateau in oxygen uptake (V̇O2) upon exhaustion, at least one of the following 25 
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should be used to confirm a maximal effort: the patient achieves a predicted V̇O2peak or peak 26 
power output (Wpeak); the patient reaches maximal heart rate (HRmax), peak ventilation 27 
approaches maximal voluntary ventilation, respiratory exchange ratio (RER) is > 1.03, 28 
exertion is 9-10 on the 0-10 scale or ≥17 on a 7-20 scale. However, our research group 29 
recently demonstrated that the use of secondary criteria to confirm a maximal effort (e.g. 30 
RER > 1.00 or 1.10, HR of 180 bmin-1 or 95% age-predicted HRmax), in line with those 31 
recommended by Hebestreit et al. [1], are invalid and can drastically underreport maximal 32 
V̇O2max in some young people with CF [4], a finding consistent with healthy children and 33 
adolescents [5]. Accepting submaximal or rejecting ‘true’ maximal values can distort the 34 
clinical application and interpretation of CPET, which is important given that V̇O2max is an 35 
indicator of prognosis [6,7], quality of life [8] and risk of hospitalisation for exacerbations [9] 36 
in people with CF.   37 
Given the limited use of secondary verification criteria to verify a maximal CPET effort in 38 
young people with CF, we have developed an alternative protocol to do so.  A procedure 39 
termed the ‘supramaximal verification phase’ (Smax), in which an exhaustive ramp 40 
incremental test precedes an exhaustive individualised constant work rate test at an intensity 41 
above Wpeak, can confirm whether a ‘true’ measure of V̇O2max has been obtained, which is 42 
fundamental to the utility of this outcome parameter in CF. Significantly, this finding is in 43 
line with data in healthy adults [10-18], children [5] and other paediatric clinical groups [19]. 44 
Although the authors present information regarding ‘was the test maximal?’, they failed to 45 
reference this published evidence and presented inaccurate verification criteria as best CPET 46 
practice for young people with CF, which we feel should be approached with caution. This 47 
statement also provides a summary of the reliability of exercise tests for young people with 48 
CF, however again published evidence has been ignored. We recently reported both the short- 49 
and medium-term reproducibility of a valid CPET protocol for young people with CF [4], 50 
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which was shown to reduce the error of measurement when compared with an isolated 51 
incremental CPET to derived V̇O2peak [20]. To the best of our knowledge we are not aware of 52 
any reproducibility or validity data for V̇O2max in young people with CF derived using the 53 
Godfrey protocol. 54 
Whilst the focus of this letter addresses validity and reproducibility issues with the Godfrey 55 
protocol, other important issues to consider are: ‘step’ increases in work rate derived 56 
exclusively from stature can result in insufficient test durations of ≤ 4 minutes [21]. This 57 
procedure limits our ability to characterise the progressive increase in V̇O2 during exercise 58 
and determine submaximal measures of aerobic fitness (e.g. the gas exchange threshold or 59 
V̇O2 mean response time) which, as highlighted in this consensus statement, may provide 60 
better predictors of mortality in adolescents with CF [22]. In accordance with others [23], we 61 
recommend a ramp incremental exercise test, which aims to reach volitional exhaustion in 8-62 
12 minutes [24], followed by Smax verification of maximal CPET parameters. Not only has 63 
this testing protocol been demonstrated as safe and feasible in young people with CF in a 64 
research setting, it is also now used as part of patients’ annual clinical review with UK based 65 
CF clinics in Exeter, Southampton and Portsmouth, demonstrating the feasibility of its 66 
clinical implementation. The CF-specific linear regression model to predict Wpeak and 67 
calculate individualised workload increments to reach volitional exhaustion in ~ 10 minutes 68 
developed by Hulzebos and colleagues should help prevent short test durations [25]. 69 
Whilst it is recognised that there are no large scale studies directly comparing exercise testing 70 
protocols, we feel the authors could have provided a more contemporary overview of the 71 
evidence concerning the validity and reproducibility of CPET protocols available for use in 72 
young people with CF. If the clinical utility of CPET to provide a comprehensive evaluation 73 
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of physiological (dys)function and stratify patients with CF is to be realised, these important 74 
practical considerations must be acknowledged.  75 
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